Vidhi Specialty Food Ingredients reported a strong second quarter for FY27, with revenue climbing 82% year-on-year to Rs 136.5 crore and profit after tax rising 66.9% to Rs 17.6 crore. Growth was driven by core operations, while the firm outlined major expansion plans in its pharma-coating and Dahej facilities. Management expects steady momentum through the second half of the year, though investors should monitor execution risks regarding new capex projects and pharma-regulatory approvals.
Vidhi Specialty Food Ingredients Reports Strong Growth and Expansion Plans
Q2 Revenue rose 82% to Rs 136.5 crore, while Q2 Profit After Tax increased 66.9% to Rs 17.6 crore.
Reader Takeaway: Robust top-line growth is supported by core operations, though investors should monitor long-lead pharma approval timelines.
What just happened
Vidhi Specialty Food Ingredients announced its Q2 FY27 results, showcasing significant year-on-year growth across key financial metrics. Consolidated revenue hit Rs 136.5 crore, significantly up from Rs 75 crore in the same quarter last year. Despite facing headwinds from higher freight costs and geopolitical instability, the company maintained strong operational momentum, delivering an EBITDA of Rs 26.4 crore for the quarter.
Business and Capex Updates
The company is aggressively moving toward capacity expansion. A Rs 75-85 crore investment in the Dahej facility is underway, with completion targeted for mid-to-end FY28, offering a revenue potential of Rs 225-250 crore. Simultaneously, the company is launching its 'CoatIcon' pharma-coating division, with a planned investment of Rs 25-35 crore to begin shortly. The pharma business is currently in the sampling phase, which typically requires a 6-12 month regulatory approval cycle before commercial scale-up.
Risks to watch
Success depends heavily on the timely execution of the Dahej plant and the regulatory approval process for the CoatIcon line. Additionally, management highlighted that ongoing geopolitical tensions in the Middle East continue to pressure logistics and freight expenses, which may impact margins. Investors have also requested more consistent investor relations and better transparency regarding site visits.
Management Outlook
Management remains optimistic, projecting that H2 FY27 performance will likely be equal to or better than the first half. The company remains committed to funding these capital expenditures through internal accruals and does not anticipate liquidity constraints despite higher temporary working capital requirements linked to inventory inflation.